Dihydropyrimidinase‐like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia

BACKGROUND: Identifying therapeutic targets and prognostic biomarkers significantly contributes to individualized treatment of acute myeloid leukemia (AML). Dihydropyrimidinase‐like 2 (DPYSL2) expression was decreased in homoharringtonine (HHT)‐resistant AML cells, which were established by our grou...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fenglin, Ling, Qing, Lian, Jiaying, Chen, Ying, Hu, Chao, Yang, Min, Zhang, Xiang, Li, Chenying, Mao, Shihui, Ye, Wenle, Li, Xia, Lin, Xiangjie, Wei, Wenwen, Huang, Xin, Pan, Jiajia, Qian, Yu, Wang, Jinghan, Lu, Ying, Jin, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134331/
https://www.ncbi.nlm.nih.gov/pubmed/36621846
http://dx.doi.org/10.1002/cam4.5531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134331/
https://www.ncbi.nlm.nih.gov/pubmed/36621846
http://dx.doi.org/10.1002/cam4.5531

Ejemplares similares